Reimagining

discovery

We are a groundbreaking immunotherapy venture studio. We accelerate early stage R/D discovery and build programs and companies, to cure diseases from COVID to Cancer.

Arrow down

Reimagining

discovery

We are a groundbreaking immunotherapy venture studio. We accelerate early stage R/D discovery and build programs and companies, to cure diseases from COVID to Cancer.

Arrow down

Immunotherapy with impact

Foundery’s studio of innovators and drug developers is focused on maximizing value creation through formation of multiple startups thematically aligned to develop and commercialize immunotherapeutics.

Bridging the “therapeutic valley of death”

Novel immunotherapeutics face a formidable therapeutic valley of death.  Successfully traversing this valley provides tremendous value to patients and investors – typically the largest step-up in a program’s lifetime.  Foundery provides the R&D infrastructure to efficiently and effectively traverse this valley.

Foundery Innovations. Engineering Success. Validated efficacy. Validated safety. Validated developability.The valley of death. Poor success rate of novel observations and targets traversing to clinical assessment.Observation. Novel observation or target identification with potential therapeutic value. Limited valuation.Clinical drug 
development candidate. NewCo formation, 
or out-licensing. Large Step-up 
in valuation.Foundery Innovations. Engineering Success. Validated efficacy. Validated safety. Validated developability.

Our Founders

Foundery was founded and is run by a storied team with exclusive access to best-in-class technologies, including the “immune archetype” platform and has an outstanding R&D track-record across multiple target areas and diseases.  Foundery’s deep knowledge of immune archetypes provides exceptional insight into the translatability of rodent biology for human disease (often an underlying cause of poor clinical success rates), as well as informing dose selection, pharmacodynamic markers, and the patient cohorts who are most likely to benefit from the therapies (the right medicine for the right patient).

Max Krummel

Max Krummel

  • Discovery and patenting of Checkpoint blockade (anti-CTLA-4 (1995;  >5B in Sales)
  • Founder of Pionyr 
(anti-TREM1/2; 2016; Gilead 1.7B deal)
  • Discovery of Archetypes in Cancer and COVID (2021)
  • Professor, UCSF

Michel Streuli

  • Organon, Schering-Plough, Merck, Gilead, and Pionyr (1.7B deal)
  • Development of multiple immunotherapies (including IntronA and Keytruda >14B in sales, Merck)
  • Harvard Medical School and Dana-Farber Cancer Institute faculty

Venkataraman “Sriram”

  • Development of Keytruda as preclinical pharmacology lead
  • Immunology and immuno-oncology R&D as well as strategy development at Schering-Plough, Merck, Gilead, and Pionyr
  • Small molecule and biologics development for immuno-oncology

Contact us

Interested in learning more? We're looking forward to hearing from you.

GET IN TOUCH
Foundery Innovations